Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Sales 105

Sales Marketing Prescription Pharma 105

Fierce Pharma

OCTOBER 31, 2023

As several new JAK inhibitors threaten Incyte’s bread-and-butter Jakafi in myelofibrosis, the company is busy advancing new regimens ahead of the drug’s 2028 patent cliff. |

312

312

European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. billion during 2028.

Medicine 95

Medicine Marketing Safety Pharmaceutical 95

Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

Sales 59

Sales FDA Marketing Competition 59

Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

Sales 52

Sales FDA Marketing Competition 52

Fierce Pharma

SEPTEMBER 27, 2023

Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. | The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. The partners plan to make Ryzumvi available in the U.S.

Pharmacology 291

Pharmacology FDA Sales 291

Fierce Pharma

FEBRUARY 8, 2024

Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.

Pharma 190

Pharma Sales Marketing 190

European Pharmaceutical Review

MARCH 20, 2024

million by 2028. percent between 2022-2028, the research found. Based on the research, the US LIMS market is predicted to value $1 billion by 2028. According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 The market is growing at a CAGR of 10.16

Marketing 97

Marketing Pharmaceutical Management Leads 97

Pharmacy Times

JANUARY 22, 2024

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

Leads 58

Leads Medicine Marketing 58

MedCity News

SEPTEMBER 8, 2022

Medical IoT is forecast to grow from $41 billion in 2020 to $188 billion by 2028. The growth is for a good reason: Connected medical devices, combined with the right software, can improve conditions and delivery, optimize care and devices, and save lives.

Medical 132

Medical 132

European Pharmaceutical Review

DECEMBER 4, 2023

billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. Moreover, the non-toxic nature of organic chemicals is expected to drive the organic chemicals sectors, ultimately boosting the pharmaceutical excipient market in the forecast period (2023 to 2028).

Marketing 95

Marketing Pharmaceutical Manufacturing Medicine 95

Pharmaceutical Commerce

JANUARY 18, 2024

The predicted value is largely driven by manufacturers' prioritization of brand protection.

Marketing 52

Marketing Manufacturing 52

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

Prescription 52

Prescription Medicine Pharma 52

Pharmaceutical Technology

JANUARY 15, 2024

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.

FDA 59

FDA 59

Pharmaceutical Commerce

SEPTEMBER 25, 2023

This would signify an 8.3% CAGR over the next five years.

Manufacturing 52

Manufacturing Marketing 52

Pharmaceutical Technology

JANUARY 9, 2024

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

52

52

Pharmaceutical Technology

JANUARY 30, 2023

These are forecast to generate $264 billion in sales between 2021 and 2028. The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028.

Sales 52

Sales Competition Leads Medicine 52

European Pharmaceutical Review

APRIL 15, 2024

The new investment in the Holly Springs facility will “add 8 x 20,000 L mammalian cell culture bioreactors by 2028, to the already planned 8 x 20,000 L for bulk drug substance as part of the initial investment”.

Manufacturing 89

Manufacturing Biopharma Networking Pharmaceutical 89

European Pharmaceutical Review

NOVEMBER 24, 2023

These activities are expected to be completed incrementally between 2026 to 2028, the company stated. While the current production facility in Chartres, France, employ around 1,600 people, once the new multi-product facilities are in operation, over 500 new jobs will be created to manage continuous production activities.

Manufacturing 98

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 98

European Pharmaceutical Review

MARCH 14, 2024

billion by 2028, based on data from Evaluate Pharma. Prior to this new facility expansion, SK bioscience highlighted that in 2021, L HOUSE was the first domestic vaccine manufacturing facility to achieve EU-GMP certification from the European Medicines Agency (EMA).

Manufacturing 89

Manufacturing Marketing Medicine Pharma 89

European Pharmaceutical Review

DECEMBER 19, 2023

The workplan, which runs until 2028, will help the European medicines regulatory network (EMRN) embrace the opportunities of AI for personal productivity, automating processes and systems, increasing insights into data and supporting more robust decision-making to benefit public and animal health.

Pharma 97

Pharma Networking Medicine Ethics 97

European Pharmaceutical Review

OCTOBER 16, 2023

The ADC market is expected to grow at a compound annual growth rate (CAGR) of 20 percent between 2023 and 2028, the contract development and manufacturing organisation (CDMO) highlighted. Enhancing manufacturing capabilities The bioconjugates market is currently valued at $33 billion according to research by Lonza.

Manufacturing 100

Manufacturing Marketing Networking Pharmaceutical 100

Pharmaceutical Technology

JANUARY 25, 2023

Despite this, Spikevax vaccine market share is expected to decline from 30% in 2022 to just 16% by the end of 2028. The therapeutic is expected to be a strong entrant in late 2023, with forecast sales of $2.5bn in 2028. One such therapeutic is PBI-0451, which is currently under development by Pardes Biosciences.

Competition 59

Competition Sales Marketing Leads 59

Pharmacy Times

AUGUST 18, 2022

Study results show a compound annual growth rate of 5.2% billion in revenue in 2021.

Marketing 26

Marketing 26

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Novo Nordisk reported an 18.2%

Marketing 52

Marketing Sales Pharma Leads 52

European Pharmaceutical Review

JUNE 28, 2023

The treatment is expected to launch in 2028 in the US, EU, and Japan. Data from the ROSE 2 trials suggests that obicetrapib in combination with ezetimibe has the potential to be used in patients who are unable to achieve sufficient LDL-cholesterol lowering with other available lipid-lowering medications,” Dr Mohammad commented.

Patients 86

Patients Sales Medical Pharmaceutical 86

Pharmaceutical Technology

SEPTEMBER 15, 2022

According to GlobalData’s report, Paxlovid, the company’s small-molecule Covid-19 oral therapy, was shown to reduce Covid-19 infections by 32% in adults and is forecast to be the top-selling drug by total sales, generating $81bn between 2021 and 2028. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%

Sales 108

Sales Competition Pharmaceutical Pharmaceutical research 108

Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. The company made a $75m up-front cash payment to EyePoint Pharmaceuticals on the closure of the deal, and an additional $7.5m will be paid in equal quarterly instalments in 2024.

Food and Drug Administration 52

Food and Drug Administration Food Pharmaceutical Sales 52

Clarify Health

NOVEMBER 28, 2022

annually through 2028. Consisting of more than a dozen applications, Atlas objectively assesses the performance of hospitals and clinicians and precisely identifies the right interventions and therapies for patients. Get valuable Insights delivered to your inbox.

Healthcare 52

Healthcare Healthcare Patients Medical 52

European Pharmaceutical Review

JANUARY 5, 2023

A 2022 market report forecasted that mRNA non-vaccine therapeutics are set to generate $2 billion in sales by 2028. The facility also offers potential for the development of vaccines for other respiratory illnesses, such as flu and respiratory syncytial virus (RSV). The future mRNA therapeutic market.

Manufacturing 59

Manufacturing Medicine Marketing Sales 59

European Pharmaceutical Review

FEBRUARY 8, 2023

Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. This allows for a large total eligible patient population despite capturing less patient share relative to other CD19 CAR-T agents.

Marketing 97

Marketing Sales Physicians Patients 97

European Pharmaceutical Review

OCTOBER 10, 2022

billion in 2028. COVID-19 vaccines have helped to prevent the illness worldwide and are a positive example of messenger RNA (mRNA)-based technology which has garnered great demand since the pandemic. Globally, the RNA-based therapeutics and vaccines market is predicted to be valued at $2.48

Training 97

Training Manufacturing Medicine Pharma 97

World of DTC Marketing

SEPTEMBER 9, 2021

Prescription drug costs are only a small part of healthcare costs, and by 2028 U.S. But even though the government may be saving money, ordinary taxpayers probably won’t see any discounts. healthcare spending will reach $6.2 trillion and account for almost 20% of the GDP. Several factors contribute to the higher cost of U.S. healthcare.

Healthcare 222

Healthcare Healthcare Government Insurance 222

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. GlobalData is the parent company of Pharmaceutical Technology. Checkpoint modulators are forecasted to retain the largest share of this, based on the webinar.

Marketing 105

Marketing Physicians Insurance Pharmaceutical 105

World of DTC Marketing

MARCH 17, 2021

Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028. For 2020, AbbVie’s handing its longtime CEO $24 million in total pay, up from 2019’s $21.6 million, the company disclosed in a proxy filing” No biosimilar will take on Humira’s $16 billion in 2020 U.S.

Pharma 186

Pharma Competition Prescription Doctors 186

Clarify Health

NOVEMBER 28, 2022

annually through 2028. Consisting of more than a dozen applications, Atlas objectively assesses the performance of hospitals and clinicians and precisely identifies the right interventions and therapies for patients.

Healthcare 40

Healthcare Healthcare Patients Medical 40